Velesco expands core scientific and quality team

Appoints director of quality and senior pharmaceutical scientist

Contract research organisation Velesco Pharmaceutical Services, which operates from facilities in Plymouth and Kalamazoo, Michigan, US, has added Shirley Smith as director of quality and Yuan Chen as senior pharmaceutical scientist.

Prior to joining Velesco, Smith was quality assurance manager for Richard-Allan Scientific and senior quality assurance manager for Pfizer’s Drug Product and Device Research Group in Kalamazoo, MI.

In conjunction with her role at Velesco, Smith will continue her leadership position at PharmaMed Resources, a quality assurance and regulatory affairs consultancy that services the Medical Device and Pharmaceutical Industries.

Chen has extensive experience in analytical methods development and validation, cleaning verification and validation, and drug release testing.

Before joining Velesco, Chen served in the Pharmaceutical Sciences Division of Pfizer Global R&D as a senior associate scientist for eight years and the Analytical Development Department of Caraco Pharmaceutical Laboratories for two years. Her experience spans the drug development spectrum from early stage development and validation of stability-indicating methods for the release of drug substance and drug product, to later stage projects focused on the detection of residual drugs on manufacturing equipment.

You may also like

Research & Development

Velesco Pharma expands and opens new cGMP-compliant analytical testing laboratory

Increases the breadth of its services to meet client needs
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Subscribe now